ABVC BioPharma (NASDAQ:ABVC) Stock Price Up 2.5% – What’s Next?

Shares of ABVC BioPharma, Inc. (NASDAQ:ABVC) shot up 2.5% on Tuesday . The stock traded as high as $1.2598 and last traded at $1.23. Approximately 41,860 shares traded hands during mid-day trading, a decline of 79% from the average session volume of 198,254 shares. The stock had previously closed at $1.20.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded ABVC BioPharma from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, June 15th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has an average rating of “Sell”.

ABVC BioPharma Stock Performance

The firm’s 50 day moving average price is $1.37 and its two-hundred day moving average price is $1.46. The company has a market cap of $31.20 million, a P/E ratio of -3.00 and a beta of 0.54.

ABVC BioPharma (NASDAQ:ABVC) last issued its earnings results on Monday, May 18th. The company reported ($0.06) earnings per share (EPS) for the quarter.

Hedge Funds Weigh In On ABVC BioPharma

A number of institutional investors and hedge funds have recently made changes to their positions in ABVC. Citadel Advisors LLC acquired a new stake in shares of ABVC BioPharma in the 3rd quarter valued at about $48,000. Millennium Management LLC acquired a new position in ABVC BioPharma during the 3rd quarter worth approximately $60,000. Finally, Geode Capital Management LLC boosted its holdings in ABVC BioPharma by 5.8% in the second quarter. Geode Capital Management LLC now owns 110,499 shares of the company’s stock worth $246,000 after acquiring an additional 6,017 shares in the last quarter. Institutional investors own 11.38% of the company’s stock.

ABVC BioPharma Company Profile

ABVC BioPharma is a clinical-stage biotechnology company focused on the discovery and development of novel vaccine and immunotherapy candidates for oncology and infectious diseases. The company leverages a proprietary peptide-based platform to identify and synthesize immunogenic epitopes, aiming to stimulate targeted immune responses against tumor-associated and pathogen-derived antigens.

The company’s pipeline includes active immunotherapy programs designed to address a range of cancer indications, along with vaccine candidates targeting bacterial pathogens.